Fluschnik Nina, Escher Felicitas, Blankenberg Stefan, Westermann Dirk
Department of General and Interventional Cardiology, University Heart Center, Hamburg Eppendorf, Hamburg, Germany.
Department of Cardiology and Pneumology, Charité Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany.
BMJ Case Rep. 2014 Sep 22;2014:bcr2014206386. doi: 10.1136/bcr-2014-206386.
We report on a challenging case of a 34-year-old male patient with giant cell myocarditis (GCM) and fulminant relapse after discontinuing immunomodulatory therapy 2 years after the initial event. Specific combined immunosuppressive therapy with antithymocyte globulin (ATG), cyclosporine and high-dose glucocorticoids combined with guideline-based heart failure medication led to the recovery of GCM, improvement of systolic left ventricular function and clinical remission. This case report emphasises the importance of an immunosuppressive therapy for the prognosis and outcome and the risk of discontinuation. Most importantly, ATG seems to be one new possible potential treatment option for patients with acute GCM.
我们报告了一例具有挑战性的病例,一名34岁男性患者患有巨细胞性心肌炎(GCM),在初次发病2年后停用免疫调节治疗后出现暴发性复发。使用抗胸腺细胞球蛋白(ATG)、环孢素和高剂量糖皮质激素进行特异性联合免疫抑制治疗,并结合基于指南的心力衰竭药物治疗,使GCM得以恢复,左心室收缩功能得到改善,临床症状缓解。本病例报告强调了免疫抑制治疗对预后和结局的重要性以及停药风险。最重要的是,ATG似乎是急性GCM患者一种新的潜在治疗选择。